skip to Main Content

No Monopoly over Hepatitis C- SIPO

A long battle over the monopoly control of Hepatitis C medicine was concluded by China's State Intellectual Property Office (SIPO). SIPO has cancelled the Patent claims for oral drug hepatitis C drug 'sofosbuvir', which was earlier granted to US pharmaceutical…

Back To Top